GSK Recall: FDA Investigates Weight Loss Drug Tampering

Mar 27, 2014

GlaxoSmithKline launched an investigation with the FDA for the over-the-counter weight-loss drug Alli on Wednesday, after consumers reported that some bottles bought in stores in seven states contained products other than the drug.

GSK announced today that the company is recalling all supplies of Alli in the United States and Puerto Rico.

Bottles affected will have clear signs of tampering, including a detached seal, removed labels, pills and capsules of all colors and sizes rather than the turquoise blue Alli capsules with a dark blue ring, as well as mismatched expiration dates.

States affected so far are Alabama, Florida, Louisiana, Mississippi, New York, North Carolina and Texas.

For more information about the recall